In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030
- Report ID: GVR-1-68038-011-8
- Number of Report Pages: 150
- Format: PDF, Horizon Databook
- Historical Range: 2018 - 2024
- Forecast Period: 2025 - 2030
- Industry: Healthcare
Market Segmentation
- Modality Outlook (Revenue, USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Model Type Outlook (Revenue, USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- GLP Type Outlook (Revenue, USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- North America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- North America Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- North America GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- U.S.
- U.S. Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- U.S. Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- U.S. Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- U.S. GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- U.S. Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Canada
- Canada Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Canada Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Canada Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Canada GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Canada Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Mexico
- Mexico Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Mexico Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Mexico Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Mexico GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Mexico Modality Outlook (Revenue in USD Million, 2018 - 2030)
- North America Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Europe
- Europe Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Europe Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Europe Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Europe GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- U.K.
- U.K. Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- U.K. Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- U.K. Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- U.K. GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- U.K. Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Germany
- Germany Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Germany Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Germany Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Germany GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Germany Modality Outlook (Revenue in USD Million, 2018 - 2030)
- France
- France Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- France Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- France Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- France GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- France Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Italy
- Italy Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Italy Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Italy Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Italy GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Italy Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Spain
- Spain Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Spain Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Spain Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Spain GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Spain Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Denmark
- Denmark Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Denmark Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Denmark Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Denmark GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Denmark Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Sweden
- Sweden Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Sweden Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Sweden Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Sweden GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Sweden Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Norway
- Norway Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Norway Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Norway Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Norway GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Norway Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Europe Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Asia Pacific
- Asia Pacific Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Asia Pacific Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Asia Pacific Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Asia Pacific GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Japan
- Japan Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Japan Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Japan Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Japan GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Japan Modality Outlook (Revenue in USD Million, 2018 - 2030)
- China
- China Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- China Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- China Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- China GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- China Modality Outlook (Revenue in USD Million, 2018 - 2030)
- India
- India Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- India Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- India Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- India GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- India Modality Outlook (Revenue in USD Million, 2018 - 2030)
- South Korea
- South Korea Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- South Korea Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- South Korea Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- South Korea GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- South Korea Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Australia
- Australia Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Australia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Australia Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Autoimmune/inflammation conditions
- Australia Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Thailand
- Thailand Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Thailand Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Thailand Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Thailand GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Thailand Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Asia Pacific Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Latin America
- Latin America Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Latin America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Latin America Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Latin America GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Brazil
- Brazil Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Brazil Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Brazil Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Brazil GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Brazil Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Argentina
- Argentina Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Argentina Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Argentina Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Argentina GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Argentina Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Latin America Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Middle East & Africa
- Middle East & Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Middle East & Africa Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Middle East & Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Middle East & Africa GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- South Africa
- South Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- South Africa Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- South Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- South Africa GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- South Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Saudi Arabia
- Saudi Arabia Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Saudi Arabia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Saudi Arabia Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Saudi Arabia GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Saudi Arabia Modality Outlook (Revenue in USD Million, 2018 - 2030)
- UAE
- UAE Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- UAE Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- UAE Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- UAE GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- UAE Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Kuwait
- Kuwait Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other
- RNA Therapy
- Others
- Cell & Gene Therapy
- Kuwait Model Type Outlook (Revenue in USD Million, 2018 - 2030)
- Rodent based
- Rat Models
- Mice Models
- Others
- Non-Rodent based
- Rodent based
- Kuwait Indication Outlook (Revenue in USD Million, 2018 - 2030)
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Pain management
- Chronic pain
- Acute pain
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Others
- Autoimmune/inflammation conditions
- Kuwait GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- Kuwait Modality Outlook (Revenue in USD Million, 2018 - 2030)
- Middle East & Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
- North America
Report content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2018 to 2030
- Market estimates and forecast for product segments up to 2030
- Regional market size and forecast for product segments up to 2030
- Market estimates and forecast for application segments up to 2030
- Regional market size and forecast for application segments up to 2030
- Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
